Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

107.60
+1.361.28%
Volume:621.12K
Turnover:67.37M
Market Cap:4.89B
PE:52.49
High:109.83
Open:108.39
Low:107.56
Close:106.24
52wk High:109.83
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:1.07
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.84
PE(LYR):52.49

Loading ...

Haemonetics Shares Rise After Citigroup Upgrade

MT Newswires Live
·
15 hours ago

Haemonetics Price Target Raised to $123.00/Share from $92.00 by Citigroup

Dow Jones
·
Yesterday

Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92

MT Newswires Live
·
Yesterday

Haemonetics Corp : Citigroup Raises to Buy from Neutral; Raises Target Price to $123 from $92

THOMSON REUTERS
·
Yesterday

Haemonetics upgraded to Buy from Neutral at Citi

TIPRANKS
·
Yesterday

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Yesterday

Orchestra Biomed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

THOMSON REUTERS
·
Sep 15

Press Release: Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Dow Jones
·
Sep 15

Intellia’s Lonvo-z Gains FDA Priority Review for HAE

TIPRANKS
·
Sep 09

Pharvaris Shares Rise on Positive Results for Hereditary Angioedema Trial

Dow Jones
·
Sep 08

Pharvaris Affirmed as Emerging Oral HAE Leader on Strong Phase 3 Data; Buy Rating Reiterated with Unchanged $60 Price Target

TIPRANKS
·
Sep 08

Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones

TIPRANKS
·
Sep 08

Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR

TIPRANKS
·
Sep 08

Pharvaris announces positive topline data from deucrictibant in HAE attacks

TIPRANKS
·
Sep 08

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

GlobeNewswire
·
Sep 08

U.S. Research Roundup-Broadcom, Deere & Co, Snowflake

Reuters
·
Sep 03

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

GlobeNewswire
·
Aug 25

Haemonetics Price Target Raised to $119.00/Share from $96.00 by Baird

Dow Jones
·
Aug 21

Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating

MT Newswires Live
·
Aug 19

Haemonetics Shares Rise After Signing Supply Agreement With CSL Plasma

MT Newswires Live
·
Aug 19